Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application for using CSPG4 (Chondroitin Sulphate Proteoglycan 4) as molecular target in treatment of triple-negative breast cancer

A triple-negative breast cancer and molecular target technology, applied in the direction of analysis of materials, anti-animal/human immunoglobulin, material inspection products, etc., can solve the problem of decreased drug sensitivity

Pending Publication Date: 2019-10-29
阳剑波
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, after multiple lines of chemotherapy, drug sensitivity decreases, and disease progression occurs within 3-6 months

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application for using CSPG4 (Chondroitin Sulphate Proteoglycan 4) as molecular target in treatment of triple-negative breast cancer
  • Application for using CSPG4 (Chondroitin Sulphate Proteoglycan 4) as molecular target in treatment of triple-negative breast cancer
  • Application for using CSPG4 (Chondroitin Sulphate Proteoglycan 4) as molecular target in treatment of triple-negative breast cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0017] Database analysis CSPG4 expression in breast cancer correlates with prognosis.

[0018] We used univariate COX regression (hazard proportional regression) analysis to analyze the prognostic correlation of CSPG4mRNA (messenger ribonucleotide) levels in 1064 primary breast cancer biopsy cases in the TCGA (proper term, untranslatable) database, KM (Kaplan-Meirer, proper noun) survival curve showed that the expression of CSPG4 in stage 1-2 breast cancer had no significant effect on prognosis (p=0.7664, figure 2 a), but the long-term (survival time greater than 6500 days (17.8 years) survival of the CSPG4 low-level group is better than that of the CSPG4 high-level group; the expression of CSPG4 in stage 3-4 breast cancer has a significant impact on prognosis (p=0.0165), The prognosis of the CSPG4 low level group was significantly better than that of the CSPG4 high level group ( figure 2 b).

[0019] Histochemical staining of CSPG4 in triple-negative breast cancer. We co...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention researches a treatment mechanism for using the CSPG4 (Chondroitin Sulphate Proteoglycan 4) as the molecular target of the immunotherapy in the treatment of the triple-negative breast cancer through the theoretical research and the experiments in vivo and vitro, provides an effective treatment of the triple-negative breast cancer, and simultaneously provides a theoretical basis for the application for using the CSPG4 (Chondroitin Sulphate Proteoglycan 4) as the antibody in the treatment of the triple-negative breast cancer.

Description

technical field [0001] The invention relates to the technical field of new application of CSPG4 in cancer treatment, in particular to the application of CSPG4 as a molecular target of immunotherapy in the treatment of triple-negative breast cancer. Background technique [0002] Breast cancer is the first malignant tumor that seriously threatens the health of women all over the world. Triple-negative breast cancer (TNBC) is defined as the hormone receptor HR (estrogen receptor ER and progesterone receptor PR) and human epidermal growth factor receptor 2 (HER2) in breast tumor tissue. Negative, accounting for 10 to 20% of all breast cancers. TNBC is a more aggressive type of breast cancer with a higher proportion of patients with advanced disease at the time of diagnosis, a higher risk of recurrence and a worse 5-year survival rate than other types of breast cancer. Compared with other breast cancer types, TNBC has the characteristics of high histological grade, strong invas...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/50A61K39/395A61P35/00
CPCG01N33/5073C07K16/18A61P35/00A61K2039/505
Inventor 阳剑波
Owner 阳剑波
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com